GHRH vs GHRP Peptides Explained

If you spend any time reading about growth-hormone peptides, you keep bumping into two acronyms that look almost identical — GHRH and GHRP — and get used as if they were interchangeable. They are not. The single letter difference (hormone vs peptide) marks two genuinely different families of molecules that release growth hormone through two separate receptors, by two different mechanisms. Understanding that split is the key that makes the entire peptide landscape legible: it explains why sermorelin and ipamorelin are not the same kind of compound, why clinics 'stack' one from each family, and where the honest evidence stops and the marketing begins.

The two families, in one sentence each

A GHRH peptide is a growth-hormone-releasing hormone analog — a synthetic copy of your body's own GHRH. It binds the GHRH receptor on the pituitary, a receptor that was molecularly cloned and shown to be pituitary-specific in 1992¹. Sermorelin (GHRH 1-29), CJC-1295, and the FDA-approved drug tesamorelin are all GHRH peptides.

A GHRP — growth-hormone-releasing peptide — is a different beast entirely. GHRPs do not act on the GHRH receptor at all. They act on the growth hormone secretagogue receptor (GHS-R), a separate receptor identified in the human brain and pituitary² whose natural ligand turned out to be the stomach hunger hormone ghrelin, discovered in 1999³. GHRP-6, GHRP-2, hexarelin, and ipamorelin are all GHRPs (ghrelin-receptor secretagogues). Strikingly, the synthetic GHRPs were discovered and characterized years before ghrelin itself — researchers had peptides that released GH long before they knew the body had its own molecule doing the same job⁴.

Mechanism: amplitude vs a second switch

The two families differ in how they raise growth hormone, and the difference is more than academic.

A GHRH peptide works by amplifying the natural GH pulse the way your own GHRH does — it tells the pituitary 'release now,' and the size of that release is still shaped by your body's own braking hormone, somatostatin. This is why GHRH analogs preserve pulsatile, physiologic GH release rather than flooding the system.

A GHRP works through a second, independent switch. Acting at the ghrelin receptor, it stimulates GH release through a mechanism centered largely at the hypothalamus — studies in patients with a disconnected hypothalamus and pituitary showed that GHRP-6's main action, and its ability to synergize with GHRH, depends on hypothalamic input⁵. Practically, a GHRP both triggers GH release and blunts somatostatin's brake, which is why it can release GH even when GHRH alone is doing the work.

The reason clinics combine them: synergy

Here is the single most important fact about GHRH vs GHRP, and the reason they are so often paired rather than chosen between: the two families are synergistic, not merely additive. In normal men, a GHRP given together with GHRH produced a growth-hormone release substantially greater than either peptide alone — the classic demonstration that the two act through complementary mechanisms that multiply rather than simply sum⁶. Later human work comparing ghrelin, hexarelin (a GHRP), and GHRH confirmed the same picture: the secretagogues and GHRH interact, with the combination exceeding what each does on its own⁷.

That synergy is the entire pharmacological rationale behind the popular 'GHRH + GHRP' stacks — for example, pairing a GHRH peptide like CJC-1295 with a GHRP like ipamorelin. One peptide pushes the accelerator (GHRH), the other adds a second accelerator while easing off the brake (GHRP), and the combined GH pulse is larger than the sum. We walk through that specific pairing in the sermorelin and ipamorelin stack.

The catch GHRPs carry: hunger and stress-hormone spillover

Because GHRPs act on the ghrelin receptor, they inherit ghrelin's other jobs. The most famous is appetite: ghrelin is the body's principal hunger signal, and GHRP-6 in particular is notorious for triggering a hunger surge. The older GHRPs (GHRP-2 and hexarelin) also tend to raise prolactin, ACTH, and cortisol when they push GH — a spillover demonstrated in a direct human comparison⁸. GHRH peptides do not carry this ghrelin-receptor baggage; they don't drive hunger and don't have the same cortisol/prolactin tendency.

This is exactly why ipamorelin became the modern GHRP of choice: when it was first characterized, its headline feature was that it released GH with potency comparable to the older GHRPs but without their cortisol and prolactin increases, and without GHRP-6's strong appetite drive⁹. So 'GHRP' is not one thing — the family ranges from the messy older compounds to the cleaner, selective ipamorelin. We compare the older three in GHRP-2 vs GHRP-6 vs hexarelin and contrast the two families directly in sermorelin vs ipamorelin.

The honest evidence line

Everything above is mechanism and short-term endocrine pharmacology — and that part is genuinely well documented in humans: we know which receptor each family hits, that they synergize, and how their GH, cortisol, and appetite effects differ, because those things were measured in controlled studies decades ago. What is not established by this mechanism is that either family safely delivers the muscle, fat-loss, or anti-aging outcomes marketed for them over months and years. Of the whole landscape, only one GHRH peptide — tesamorelin — is FDA-approved, and only for a narrow indication (HIV-associated visceral fat). Sermorelin is compounded and off-label; CJC-1295, GHRP-6, GHRP-2, hexarelin, and ipamorelin are research-grade compounds with no manufacturer label and no long-term outcome trials. A synergistic GH pulse on a lab graph is not the same as a proven result in your body. We keep that line strict in our pillar guide, Sermorelin for Sleep, Recovery & Healthy Aging.

The bottom line

GHRH and GHRP are two different keys for two different locks. GHRH peptides (sermorelin, CJC-1295, tesamorelin) copy your own releasing hormone and act on the GHRH receptor, amplifying a physiologic GH pulse without driving hunger. GHRPs (ipamorelin, GHRP-6, GHRP-2, hexarelin) act on the ghrelin receptor — a separate switch that both triggers GH and lifts the somatostatin brake, but can bring appetite and, for the older ones, cortisol and prolactin spillover. Their defining relationship is synergy: combined, they release more GH than either alone⁶, which is the real reason the two are stacked rather than ranked. But the documented evidence is short-term receptor pharmacology, not proof of long-term results — and outside FDA-approved tesamorelin, these are off-label or research compounds. For the GHRP that solved the spillover problem, see CJC-1295 benefits; to see how prescribed GH-peptide providers compare, read our guide to the best sermorelin providers.